Appendix 4C - Quarterly - 30 September 2025
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights the successful completion of a fully underwritten entitlement offer and ongoing assessments of new assets to diversify shareholder risk. Additionally, the company is pursuing partnering and licensing opportunities for its deoxymab assets, with a cash balance reported at the end of the quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Patrys Receives R&D Tax Incentive Refund
- Notice of Annual General Meeting/Proxy Form
- Appendix 4E - Preliminary Final Report
- Appendix 4C - Quarterly - 30 June 2025
- Entitlement Offer Prospectus
Later from Patrys
- Trading Halt
- Pipeline Expanded with Proprietary Injectable Antipsychotic
- Completion of Acquisition and Board Appointments
- Investor Presentation
- Appendix 4C - Quarterly - 31 December 2025
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys